{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03863002",
      "OrgStudyIdInfo": {
        "OrgStudyId": "Tianjin Weikai Bioeng., Ltd"
      },
      "Organization": {
        "OrgFullName": "Tianjin Weikai Bioeng., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure",
      "OfficialTitle": "Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2018",
      "OverallStatus": "Not yet recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "October 1, 2019",
        "StartDateType": "Anticipated"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "October 1, 2021",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "October 1, 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "February 18, 2019",
      "StudyFirstSubmitQCDate": "March 2, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 5, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "March 18, 2019",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "March 20, 2019",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Tianjin Weikai Bioeng., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Tianjin Nankai Hospital",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "Safety and Efficacy of Mesenchymal Stem Cell Transplantation for Acute-on-Chronic Liver Failure",
      "DetailedDescription": "Acute-on-chronic liver failure (ACLF) which occurs in patients with chronic liver disease, is a serious live-threatening disease. Currently, the clinical management, such as liver protection, anti-virus medicine, and artificial liver support, has not significantly improve the outcomes, the mortality still remains over 50%. Liver transplantation is the only effective treatment of ACLF, but this therapy is limited by the shortage of donor organs, potential surgical complications, immunological rejection and high medical costs. Mesenchymal stem cell (MSC) is one of adult stem cells, which has been suggested to play a role in amelioration of liver disease, such as: trans-differentiation of MSCs into hepatocytes, immunomodulation, inhibition of fibrosis development, protective effects on hepatic cell and restoration of hepatic cell proliferation capacity."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Liver Failure, Acute on Chronic"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "mesenchymal stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)",
          "DesignMaskingDescription": "both participants and the study team are unblinded to the treatment allocation"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "45",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Standard Medical Treatment",
            "ArmGroupType": "No Intervention",
            "ArmGroupDescription": "Standard Medical Treatment (SMT): All patients received SMT, including nutritional supplementation; administration of human serum albumin (serum albumin <30 g/L), fresh frozen plasma (200-400 mL/day until the INR was <1.5), S-adenosylmethionine (1.0 g/day); or anti-virus treatment for hepatic viruses-related cases, and appropriate treatment for complications such as infections (including of the respiratory tract, urinary tract, biliary tract, and digestive tract and spontaneous peritonitis), encephalopathy, gastrointestinal bleeding, and hepatorenal syndrome [HRS])."
          },
          {
            "ArmGroupLabel": "Mesenchymal Stem Cell",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Mesenchymal Stem Cell (MSC): The MSC group received infusions of 1.0 to 10x10^5cells/kg MSCs through the peripheral vein once a week for 4 weeks, in addition to SMT.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Mesenchymal Stem Cell"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Mesenchymal Stem Cell",
            "InterventionDescription": "Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal Stem Cell"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "survival rate",
            "PrimaryOutcomeDescription": "Number of participants alive",
            "PrimaryOutcomeTimeFrame": "72 weeks after treatment"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Adverse reactions",
            "SecondaryOutcomeDescription": "Number of participants with adverse reactions (e.g. fever, rash, and diarrhea )",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "White blood cell",
            "SecondaryOutcomeDescription": "Change of white blood cell count",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "Platelet",
            "SecondaryOutcomeDescription": "Change of platelet count",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "Hemoglobin",
            "SecondaryOutcomeDescription": "Change of hemoglobin level",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "Creatinine",
            "SecondaryOutcomeDescription": "Change of creatinine level as a surrogate marker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "ALT",
            "SecondaryOutcomeDescription": "Change of alanine aminotransferase (ALT) level as a marker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "ALB",
            "SecondaryOutcomeDescription": "Change of albumin (ALB) level as a maker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "TBil",
            "SecondaryOutcomeDescription": "Change of total Bilirubin (TBil) level as a marker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "INRs",
            "SecondaryOutcomeDescription": "Change of international normalized ratio (INRs) level as a marker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "AFP",
            "SecondaryOutcomeDescription": "Change of alpha fetoprotein (AFP) level as a marker of liver function",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "MELD scores",
            "SecondaryOutcomeDescription": "Model for End-Stage Liver Disease (MELD) score for assessing the severity of chronic liver disease is measured as absolute change to baseline score",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "Tumor formation",
            "SecondaryOutcomeDescription": "Number of participants with hepatocellular carcinoma or extrahepatic malignant tumors",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          },
          {
            "SecondaryOutcomeMeasure": "Liver failure-associated serious complications",
            "SecondaryOutcomeDescription": "Number of participants with liver failure-associated serious complications, such as infections, encephalopathy, gastrointestinal bleeding and HRS",
            "SecondaryOutcomeTimeFrame": "Week 1, 2, 4, 8, 12, 24, 36, 48"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nInformed consent\nMeeting the definition of ACLF: patients with previously diagnosed or undiagnosed chronic liver disease acute decompensated within 4 weeks; significant GI symptom as such fatigue, jaundice; serum total bilirubin [TBil] ≥10 X the upper limit of normal; coagulopathy (international normalized ratio [INR] ≥1.5 or prothrombin activity [PTA] <40%); complicated within 4 weeks by ascites and/or encephalopathy as determined by physical examination.\nModel for End-Stage Liver Disease (MELD) scores ranging 17-30, (MELD(i) = 0.957 × ln(Cr) + 0.378 × ln(bilirubin) + 1.120 × ln(INR) + 0.643);\nChronic liver disease with definitive etiology such as viral hepatitis, alcohol liver disease, drug induced liver injury or autoimmune liver diseases\nBody weight ≥50kg\n\nExclusion Criteria:\n\nSerious complications in the previous 2 months (e.g., gastrointestinal bleeding: hemoglobin below 90g/L, serious infection such as sepsis, ascites ultrafiltration, and/or dialysis);\nMalignant jaundice induced by obstructive jaundice or hemolytic jaundice;\nHepatocellular carcinoma (HCC) diagnosed by radiologic imaging and/or alpha fetoprotein (AFP);\nTumor diagnosed by ultrasound, CT, MR examination;\nModerate or severe chronic heart failure (NYHA III-IV), renal replacement therapy, severe chronic pulmonary disease (GOLD III-IV)\nExtrahepatic cholestasis\nHepatic, portal and splenic vein thrombosis diagnosed by doppler ultrasound\nArtificial liver support\nPrevious liver transplantation\nDrug abuse in the past 5 years;\nMental disorders and/or has a family history of mental disorder.\nHIV infection\nPregnant or breast-feeding females\nHighly allergic\nPatients can not cooperate or mobility\nEnrolled in other clinical trials with 3 months\nPatients who can not provide prior informed consent or refusal to participate",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "16 Years",
      "MaximumAge": "60 Years",
      "StdAgeList": {
        "StdAge": [
          "Child",
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Xiuli Cong, MD, PhD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "+86 18512507567",
            "CentralContactEMail": "cong_xiuli@163.com"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Tianjin Weikai Bioeng., Ltd.",
            "LocationCity": "Tianjin",
            "LocationState": "Tianjin",
            "LocationCountry": "China",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Xiuli Cong, MD, PhD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "+86 18512507567",
                  "LocationContactEMail": "cong_xiuli@163.com"
                }
              ]
            }
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000017093",
            "ConditionMeshTerm": "Liver Failure"
          },
          {
            "ConditionMeshId": "D000048550",
            "ConditionMeshTerm": "Hepatic Insufficiency"
          },
          {
            "ConditionMeshId": "D000058625",
            "ConditionMeshTerm": "End Stage Liver Disease"
          },
          {
            "ConditionMeshId": "D000065290",
            "ConditionMeshTerm": "Acute-On-Chronic Liver Failure"
          },
          {
            "ConditionMeshId": "D000017114",
            "ConditionMeshTerm": "Liver Failure, Acute"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000008107",
            "ConditionAncestorTerm": "Liver Diseases"
          },
          {
            "ConditionAncestorId": "D000004066",
            "ConditionAncestorTerm": "Digestive System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M28321",
            "ConditionBrowseLeafName": "End Stage Liver Disease",
            "ConditionBrowseLeafAsFound": "Chronic Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18567",
            "ConditionBrowseLeafName": "Liver Failure",
            "ConditionBrowseLeafAsFound": "Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M25123",
            "ConditionBrowseLeafName": "Hepatic Insufficiency",
            "ConditionBrowseLeafAsFound": "Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M29651",
            "ConditionBrowseLeafName": "Acute-On-Chronic Liver Failure",
            "ConditionBrowseLeafAsFound": "Acute on Chronic Liver Failure",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M18583",
            "ConditionBrowseLeafName": "Liver Failure, Acute",
            "ConditionBrowseLeafAsFound": "Liver Failure, Acute",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10259",
            "ConditionBrowseLeafName": "Liver Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8035",
            "ConditionBrowseLeafName": "Gastrointestinal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M6407",
            "ConditionBrowseLeafName": "Digestive System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC06",
            "ConditionBrowseBranchName": "Digestive System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "M10262",
            "InterventionBrowseLeafName": "Liver Extracts",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "Hemat",
            "InterventionBrowseBranchName": "Hematinics"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}